Interaction Checker

Interacciones de Alpelisib

Alpelisib (Piqray, Vijoice) tiene 77 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 32; moderadas: 45; leves: 0; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (32)

  • Aprepitantinhibidor de CYP3A4Grave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • Armodafiniloestimulante del SNCGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • Bosentáninductor de CYP3A4Grave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • CarbamazepinaanticonvulsivoGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • CenobamatoanticonvulsivoGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • ClobazambenzodiazepinaGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • Deferasiroxsuplemento de hierroGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • DexametasonacorticosteroideGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • EfavirenzantirretroviralGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • Efavirenz, lamivudina y tenofovirantirretroviralGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • EslicarbazepinaanticonvulsivoGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • EtravirinaantirretroviralGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • FenobarbitalbarbitúricoGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • Fentermina y topiramatoestimulante del SNCGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • FosfenitoínaanticonvulsivoGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • GriseofulvinaantifúngicoGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • Lopinavir y ritonavirantirretroviralGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • Lorlatinibinductor de CYP3A4Grave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • Mitapivatinductor de CYP3A4Grave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • Mitotanoinductor de CYP3A4Grave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • Modafiniloestimulante del SNCGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • Nafcilinaantibiótico del grupo de las penicilinasGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • NevirapinaantirretroviralGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • OxcarbazepinaanticonvulsivoGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • PrimidonaanticonvulsivoGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • RifabutinaantibióticoGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • RifampicinaantibióticoGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • RifapentinaantibióticoGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • RitonavirantirretroviralGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • Suzetriginainductor de CYP3A4Grave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

  • TopiramatoanticonvulsivoGrave

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

Interacciones moderadas (45)

  • AzelastinaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • Azelastina y fluticasonaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • BeclometasonacorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • BetametasonacorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • Bromfeniramina, pseudoefedrina y dextrometorfanoantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • BudesonidacorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • Budesonida y formoterolcorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • CarbinoxaminaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • CetirizinaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • CiclesonidacorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • CiproheptadinaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • ClemastinaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • ClobetasolcorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • ClorfenaminaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • DeflazacortcorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • DesloratadinaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • DesonidacorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • DexclorfeniraminaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • DifenhidraminaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • DimenhidrinatoantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • DoxilaminaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • Doxilamina y piridoxinaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • FexofenadinaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • FludrocortisonacorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • FlunisolidacorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • FluocinonidacorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • FluticasonacorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • Fluticasona y salmeterolcorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • HalobetasolcorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • Hidrocodona y clorfenaminaopioideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • HidrocortisonacorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • HidroxizinaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • LevocetirizinaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • LoratadinaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • MeclozinaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • MetilprednisolonacorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • MometasonacorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • OlopatadinaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • Olopatadina y mometasonaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • PrednisolonacorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • PrednisonacorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • PrometazinaantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • Prometazina y codeínaopioideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • Prometazina y dextrometorfanoantihistamínicoModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • TriamcinolonacorticosteroideModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

Compruebe Alpelisib frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.